目的 探究采用癇愈膠囊聯(lián)合丙戊酸鎂治療癲癇患者的臨床效果。方法 選取響水縣人民醫(yī)院2014年1月-2016年12月收治的81例癲癇患者為研究對象，隨機(jī)分成對照組（40例）和治療組（41例）。對照組患者口服丙戊酸鎂緩釋片，1片/次，2次/d。治療組患者在對照組基礎(chǔ)上口服癇愈膠囊，5片/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組患者臨床療效，比較治療前后兩組患者癲癇發(fā)作次數(shù)、ADL評分、藥物保留率和不良反應(yīng)。結(jié)果 治療后，對照組和治療組臨床總有效率分別為82.50%和97.56%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的癲癇發(fā)作次數(shù)明顯降低，ADL評分均明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者癲癇發(fā)作次數(shù)和ADL評分均要明顯優(yōu)于對照組患者（P<0.05）。治療24、36周后，治療組藥物保留率分別80.88%和60.29%，均明顯高于對照組62.69%、40.30%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間，對照組不良反應(yīng)發(fā)生率為22.50%，顯著高于治療組的4.88%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 癇愈膠囊聯(lián)合丙戊酸鎂治療癲癇患者具有顯著的臨床療效，且安全性好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Xianyu Capsules combined with magnesium valproate in treatment of epilepsy. Methods Patients (81 cases) with epilepsy in Xiangshui People's Hospital from January 2014 to December 2016 were randomly divided into control (40 cases) and treatment (41 cases). Patients in the control group were po administered with Magnesium Valproate Sustained Release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Xianyu Capsules on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the seizure frequency and ADL score, the drug retention rate and adverse events in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.50% and 97.56% respectively, and there were differences between two groups (P < 0.05). After treatment, the seizure frequency in two groups was significantly decreased, but ADL score was significantly increased, and the difference was statistically significant in the same group (P < 0.05), and the seizure frequency and ADL score in the treatment group were significantly better than those in the control group (P < 0.05). After treatment for 24 and 36 weeks, the drug retention rate in the treatment group was 80.88% and 60.29%, which was significantly higher than 62.69% and 40.30% in the control group, respectively, and there were differences between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 22.50%, which was significantly higher than 4.88% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Xianyu Capsules combined with magnesium valproate has significant clinical efficacy in treatment of epilepsy with high safety, which has a certain clinical application value.